Showing papers in "Annals of Oncology in 2006"

TL;DR: The total number of new cases of cancer in Europe appears to have increased by 300,000 since 2004 and the ageing of the European population will cause these numbers to continue to increase even if age-specific rates remain constant.

TL;DR: Evidence that up- or down-regulation of the multiple membrane transporters, target enzymes, enzymes involved in the metabolism of gemcitabine and alterations in the apoptotic pathways may confer sensitivity/resistance to this drug has been provided in experimental models and more recently in the clinical setting.

TL;DR: Socio-economic differences in cancer survival are now well documented and the explanatory power of stage at diagnosis, although great, should not detract from the evidence of differential treatment between social groups.

TL;DR: Abraxane 260 mg/m2 administered IV over 30 min without premedication was well tolerated and significant tumor responses and prolonged disease control were documented in this group of patients with NSCLC.

TL;DR: DC vaccination could not be demonstrated to be more effective than DTIC chemotherapy in stage IV melanoma patients, and the observed association of overall performance status and HLA haplotype with overall survival for patients treated by DC vaccination should be tested in future trials employing DC vaccines.

TL;DR: In this article, the authors summarized the recent trends in the epidemiology and survival of cancers in the developing and developed world, and explored potential causes and policy responses to the disproportionate and growing cancer burden in less developed countries.

TL;DR: Using data from 9524 women with early breast cancer who were randomized in International Breast Cancer Study Group clinical trials between 1978 and 1999, a group at sufficient risk to justify routine screening for occult central nervous system metastases was not defined.

TL;DR: A number of strategies to develop formulations of surfactant-free taxanes have been developed, which include albumin nanoparticles, polyglutamates, taxane analogs and prodrugs, emulsions, and lipsomes.

TL;DR: Single-dose palonosetron was as effective as ondansetron in preventing acute CINV following HEC, and with dexamethasone pre-treatment, its effectiveness was significantly increased over ondANSetron throughout the 5-day post-chemotherapy period.

TL;DR: This retrospective study further validates ER CC1 and RRM1 genes as reliable candidates for customized chemotherapy and shows a higher impact on the survival of NSCLC patients treated with cisplatin/gemcitabine for ERCC1.

TL;DR: Recommendations about antiemetic prophylaxis in patients receiving treatment with chemo- and radiotherapy have been updated by representatives of nine oncological organizations.

TL;DR: Combination of EGFR FISH and IHC is effective predictor for benefit from gefitinib, and patients with double-negative results are unlikely to benefit in western NSCLC populations.

TL;DR: Treatment with imatinib increases survival of patients with advanced disease with a few years and is associated with only moderate toxicity, and other tyrosine kinase inhibitors as treatments of advanced GIST.

TL;DR: The rationale exists for the use of somatostatin analogs as antitumor agents, and studies are ongoing to identify analogs with activity across the range of receptor subtypes to maximize the potential of such treatment.

TL;DR: Prescribing clinicians should be familiar with these possible adverse effects of intravenous bisphosphonates and discuss them with patients before commencing or continuing on therapy.

TL;DR: Concomitant platin-based radio-chemotherapy may improve survival of patients with locally advanced NSCLC, however, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.

TL;DR: The data suggest that patients with sub-micrometastases in the SN may be judged as SN negative, as non-stage III, and are highly unlikely to benefit from CLND, which is no longer recommend.

TL;DR: Measurement of PgR status in ER-negative patients defines a group of patients that benefit from tamoxifen but would be excluded from tamxifen therapy on the basis of ER status alone, consistent with HER2 positive tumours being resistant to tamoxIFen.

TL;DR: The vaginal estradiol tablet Vagifem significantly raises systemic Estradiol levels, at least in the short term, which reverses the estradio suppression achieved by aromatase inhibitors in women with breast cancer and is contraindicated.

TL;DR: Addition of cetuximab to weekly infusional 5-FU/FA plus irinotecan is safe and first data suggest a promising activity, and the5-FU dose of 1500 mg/m(2) is recommended for further studies.

TL;DR: The aprepitant regimen was superior in the acute, delayed and overall phases of chemotherapy-induced nausea and vomiting and should be considered a new standard of antiemetic therapy for cisplatin-treated patients.

TL;DR: It is found that primary mediastinal large B-cell lymphoma patients have excellent survival rates and a distinct plateau is observed in PFS, in striking comparison to DLBCL.

TL;DR: Switching to anastrozole after the first 2-3 years of treatment was confirmed to improve event-free and relapse-free survival of postmenopausal, node-positive, ER-positive early breast cancer patients already receiving adjuvant tamoxifen.

TL;DR: Dalteparin prophylaxis did not reduce the frequency of thromboembolic complications after CVC implantation in cancer patients and was demonstrated to be safe over 16 weeks of treatment in these patients.

TL;DR: Results show that monitoring concordance between MDT decisions and final treatment implementation is useful to inform team decision-making and require more information about co morbid disease and patient choice to truly optimize the implementation of multi-disciplinary expertise.

TL;DR: In cancer patients the risk of VTE steadily increases with the number of risk factors, and identification of patients at high risk is possible.

TL;DR: Arsenic trioxide is effective as first-line treatment for APL and results of arsenic trioxide combination therapy with chemotherapy/ATRA requires further study.

TL;DR: Immunohistochemical studies for ERCC1 may be useful in prediction of the clinical outcome in advanced gastric cancer patients treated with 5-FU and oxaliplatin.

TL;DR: Fenretinide induces a significant risk reduction of second breast cancer in premenopausal women, which is remarkable at younger ages, and persists several years after treatment cessation, and a trial in young women at high-risk is warranted.

TL;DR: Breast MSC and carcinosarcoma are aggressive, treatment-refractory tumors with shared clinical features and outcome similar to poorly differentiated receptor-negative adenocarcinomas.